Connect With Us

Inside INdiana Business
Subscribe Now Log In
  • Home
  • News
    • Education
    • Health
    • Tech
    • STEM
    • Advanced Manufacturing & Logistics
    • Life Sciences
    • Ag INnovation
    • INPower
  • Videos
  • Big Wigs
    • Submit Big Wigs
  • Events
    • Engage Southwest Indiana – Evansville
    • Engage Northwest Indiana – Valparaiso
    • Engage Greater Lafayette – West Lafayette
    • Engage West Central Indiana – Terre Haute
    • Engage South Bend – Elkhart
    • Engage Northeast Indiana – Fort Wayne
    • Engage Central Indiana – Indianapolis
  • Newsletters
  • Podcasts
  • On-Air
    • TV & Radio Listings
  • Contact
    • About IIB
    • Meet the Team
    • Contact Us
    • Advertise
    • Gift Cards
    • Flagship Stations
    • Gerry’s Message
    • Speaking Engagement Request

Connect With Us

Lilly Pauses COVID-19 Antibody Trial

Tuesday, October 13, 2020 04:44 PM EDT Updated: Wednesday, October 14, 2020 09:17 AM EDT
By Alex Brown
Lilly Pauses COVID-19 Antibody Trial (photo courtesy of Eli Lilly and Co.)

Indianapolis-based Eli Lilly and Co. (NYSE: LLY) has paused its trial of an antibody treatment for COVID-19. While a specific reason for the pause was not provided, the pharmaceutical company says the decision was made “out of an abundance of caution.”

Lilly’s investigational neutralizing antibody, known as LY-CoV555, was being tested in an ACTIV-3 study led by the National Institutes of Health. ACTIV stands for “Accelerating COVID-19 Therapeutic Interventions and Vaccines” and is a public-private partnership that launched in April, according to the NIH website.

The company says the study’s independent data safety monitoring board recommended the pause.

“The trial, evaluating Lilly’s investigational neutralizing antibody as a treatment for COVID-19 in hospitalized patients, is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH),” a Lilly spokesperson said in a statement. “Lilly is supportive of the decision by the independent DSMB to cautiously ensure the safety of the patients participating in this study.”

Lilly did not specify whether an unexpected illness was the reason to pause the study or if other factors were involved.

The study is one of several being conducted to test the use of the antibody treatment in various settings. 

In other trials not connected to the ACTIV-3 study, Lilly said earlier this month the combination of LY-CoV555 with another antibody resulted in lower rates of COVID-related hospitalization and ER visits. 

The company said it planned to submit a request with the Food and Drug Administration for an Emergency Use Authorization for a combination antibody therapy in November, though it is unclear if those plans have been delayed.

Story Continues Below

Most Popular Stories

  • An Angola company is making tech last longer. Its mission has led to big growth.

  • Shoe Carnival names new CFO

  • Evansville’s West Side Nut Club Fall Festival tops USA Today’s list of best fall festivals

  • Purdue to develop SARS-CoV-2 animal field test

  • Lilly to install $10M worth of solar panels at two Indy campuses

  • Indiana utilities outline outages, responses to major storms

Perspectives

Biodefense Commission heads to IMS for a public meeting on the perpetual race against biological threats

Biodefense Commission heads to IMS for a public meeting on the perpetual race against biological threats

The Indianapolis Motor Speedway has hosted countless legendary events for well over 100 years. Along with Lucas Oil Stadium, Gainbridge Fieldhouse and the Indiana Convention Center, Indianapolis hosts countless large scale, mass-gathering events. It is part of what makes this city so dynamic and special. ...

Inside INdiana Business

Inside INdiana Business
A division of IBJ Media

1 Monument Circle, Suite 300
Indianapolis, IN 46204

PHONE: (317) 634-6200

FAX: (317) 263-5060

NEWSLETTER@IIBNEWS.COM

  • Home
  • News
  • Videos
  • Gerry Dick
  • Newsletters
  • On-Air
  • Contact

Copyright © 2023 All Rights Reserved Privacy Policy | Terms of Service